Department of Medicine for Orthopaedics and Motor Organ, Juntendo University Graduate School of Medicine, Tokyo, Japan.
Department of Orthopaedic Surgery, University of Occupational and Environmental Health, Fukuoka, Japan.
Osteoarthritis Cartilage. 2022 Jun;30(6):852-861. doi: 10.1016/j.joca.2022.03.003. Epub 2022 Mar 22.
We previously reported, based on a multicenter randomized-control study, that the efficacy of intra-articular injections of hyaluronic acid (IA-HA) was not inferior to that of oral non-steroidal anti-inflammatory drugs (NSAIDs) in patients with knee osteoarthritis (OA). However, the molecular effects on the pathophysiology of knee OA remain unclear. C-terminal telopeptides of type II collagen (CTX-II) is reported to primarily originate from the interface between articular cartilage and subchondral bone, which is a site of potential remodeling in OA. We performed a predefined sub-analysis of the previous study to compare the changes of urinary CTX-II (uCTX-II) in response to IA-HA to those in response to NSAID for knee OA.
A total of 200 knee OA patients were registered from 20 hospitals and randomized to receive IA-HA (2,700 kDa HA, 5 times at 1-week intervals) or NSAID (loxoprofen sodium, 180 mg/day) for 5 weeks. The uCTX-II levels were measured before and after treatment.
The uCTX-II levels were significantly increased by IA-HA treatment (337.7 ± 193.8 to 370.7 ± 234.8 ng/μmol Cr) and were significantly reduced by NSAID treatment (423.2 ± 257.6 to 370.3 ± 250.9 ng/μmol Cr). The %changes of uCTX-II induced by IA-HA (11.6 ± 29.5%) and NSAID (-9.0 ± 26.7%) was significantly different (between-group difference: 20.6, 95% confidence intervals: 10.6 to 30.6).
While both IA-HA and NSAID improved symptoms of knee OA, uCTX-II levels were increased by IA-HA and reduced by NSAIDs treatment, suggesting these treatments may improve symptoms of knee OA through different modes of action.
我们之前基于一项多中心随机对照研究报道,关节内注射透明质酸(IA-HA)的疗效并不逊于口服非甾体抗炎药(NSAIDs)治疗膝骨关节炎(OA)。然而,其对膝 OA 病理生理学的分子作用仍不清楚。II 型胶原 C 末端肽(CTX-II)主要来源于关节软骨和软骨下骨的界面,这是 OA 潜在重塑的部位。我们对之前的研究进行了预设的亚分析,比较了 IA-HA 和 NSAID 治疗膝 OA 时尿 CTX-II(uCTX-II)的变化。
从 20 家医院共登记了 200 例膝 OA 患者,并随机分为 IA-HA(2700 kDaHA,每周 1 次,共 5 次)或 NSAID(洛索洛芬钠,每天 180mg)治疗组,共 5 周。治疗前后测量 uCTX-II 水平。
IA-HA 治疗后 uCTX-II 水平显著升高(337.7±193.8 至 370.7±234.8ng/μmol Cr),NSAID 治疗后显著降低(423.2±257.6 至 370.3±250.9ng/μmol Cr)。IA-HA(11.6±29.5%)和 NSAID(-9.0±26.7%)引起的 uCTX-II 的变化%显著不同(组间差异:20.6,95%置信区间:10.6 至 30.6)。
尽管 IA-HA 和 NSAID 均改善了膝 OA 的症状,但 IA-HA 可增加 uCTX-II 水平,而 NSAIDs 治疗可降低其水平,提示这些治疗方法可能通过不同的作用机制改善膝 OA 的症状。